Plasmid News and Research

RSS

Impact of DNA clearance on mortality in patients with severe COVID-19 infections

In a new study, researchers conducted activity-based proteomic profiling of patients who had severe SARS-CoV-2 infections to understand the impact of DNA clearance on mortality.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

16 Jan 2022

Cannabidiol may improve innate immune response against SARS-CoV-2

A recent study shows evidence that cannabidiol, an important active ingredient in the Cannabis sativa plant, can augment the antiviral innate immune response and prophylactically prime the innate antiviral response of cells – enabling in turn improved response against viruses such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Jan 2022

Virus-like particles as delivery vehicles for gene-editing

Scientists deliver gene-editing proteins through the use of engineered virus-like particles, which mediated efficient base editing both in vitro and in vivo.

13 Jan 2022

Exploring factors favoring transmission of SARS-CoV-2 Delta sublineage AY.4.2 over the Delta variant

In the present study, researchers isolated an infectious AY.4.2 strain of COVID-19 from the nasopharyngeal swab of a symptomatic individual from the Paris region. Then, they introduced the AY.4.2 signature mutations - T95I, Y145H, and A222V - in an expression plasmid coding the Delta protein to study the function of the AY.4.2 S protein.

13 Jan 2022

Curia unveils comprehensive mRNA solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle formulation and development for full-scale sterile fill-finish services.

From Curia Global, Inc. 7 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

New compound could combat multidrug-resistant pathogens in healthcare settings

For years, public-health experts have been sounding the alarm about the next phase in humanity's co-existence with bacteria - a dark future where emerging strains have rendered once-powerful antibiotics useless.

5 Jan 2022

Unique nanoparticle can deliver genome editing technology to endothelial cells

The lab of Youyang Zhao, PhD, from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which are cells that line blood vessel walls.

4 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

16 Dec 2021

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

A new study assessed nAb activities against five strains of SARS-CoV-2 in paired maternal and infant cord blood samples.

15 Dec 2021

Researchers introduce new method for observing cell interactions

Researchers created a system that allows scientists to ‘log’ a cell’s reactions to external stimuli within the cell’s genetic material.

2 Dec 2021

Severe COVID-19 may result in premature aging in recovered patients

As COVID-19 has been found to cause frontal cortex impairment similar to aging, the scientists in a recent study attempted to investigate if severe COVID-19 resulted in aging-related molecular signatures in the brain. The findings from this study are published as a preprint on the medRxiv* server.

28 Nov 2021

Antigenic cocktail produced in Nicotiana benthamian plant as a potential COVID-19 vaccine candidate

Scientists utilize N. benthamiana for producing the N-protein and an antigenic cocktail containing the N-protein and SARS-CoV-2 S RBD.

23 Nov 2021

A nasal COVID vaccine using a weakened influenza vector

The authors of a new study, published on the bioRxiv* preprint server, constructed a COVID-19 nasal vaccine candidate by inserting a gene encoding the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2, named CA4-dNS1-nCoV-RBD (dNS1-RBD) in a live attenuated influenza virus (LAIV) vector.

18 Nov 2021

Novel strategy to produce SARS-CoV-2 nucleocapsid protein for serological testing

New research discusses an alternative method of purifying the SARS-CoV-2 N protein using only metal exchange chromatography and denaturing conditions.

18 Nov 2021

Interactions between SARS-CoV-2 S protein and ACE2 receptor using fluorescence correlation spectroscopy

Researchers used advanced two-color fluorescence cross-correlation spectroscopy to demonstrate the interaction between human ACE2 and the S1 subunit of SARS-CoV-2 and SARS-CoV.

17 Nov 2021